In Vivo Toxicology Market – Anticipated To Witness High Growth In The Near Future

In Vivo Toxicology Market

PUNE, India, 2020-Apr-16 — /EPR Network/ —

Some key factors driving market growth are the increasing pharmaceutical R&D activities, mandatory government regulations for animal testing, innovations in animal models, and the development of exclusive in vivo toxicology tests. Factors such as increasing research in oncology and personalized medicine and the rising demand for humanized animal models are expected to offer lucrative opportunities for players in the global market.

[196 Pages Report] The Global In Vivo Toxicology Market is expected to grow at a CAGR of 6.9% during the forecast period to reach to USD 6.14 Billion.

Objectives of the Study

• To define, describe, and forecast the global market by product, testing type, toxicity endpoint, testing facility, and region
• To provide detailed information regarding the major factors influencing the growth of the global market (drivers, restraints, opportunities, and challenges)
• To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East Africa

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811

Market Segmentation in Detailed Analysis:

Based on testing type, the market is segmented into chronic, sub-chronic, sub-acute, and acute toxicology testing. In 2017, the chronic toxicity testing segment is expected to account for the largest share of the global market. Increasing research focused on drugs used for long-duration therapies such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives is driving the growth of the chronic toxicity testing market. However, the sub-acute toxicity testing segment is expected to register the highest CAGR of during the forecast period.

By toxicity endpoint, the market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). The immunotoxicity segment is expected to account for the largest share of the global market in 2017, followed by the systemic toxicity segment. The rising demand for the development of biologics and Biosimilars is driving the growth of the immunotoxicity segment.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811

Geographically, North America is estimated to dominate the market in 2017 with the highest market share in the market. The largest share of this regional segment is attributed to the increasing investments in R&D activities, scientific developments in biotechnology, and the presence of major pharmaceutical and preclinical testing companies in the region. However, Latin America (LATAM) is expected to grow at the highest CAGR during the forecast period. Factors such as the flourishing pharmaceutical and biopharmaceutical industry in Brazil in turn propelling the drug development activities and increase in the number of CROs that offer cost-effective in vivo toxicology services are driving the growth of the global market in LATAM.

The major players in the global market include Thermo Fisher (US), Danaher (US), Charles River (US), Covance (LabCorp), Eurofins (Luxembourg), Envigo (US), DSI (US), and The Jackson Laboratory (US).